The FDA has added its strictest warning to arthritis drugs manufactured by Pfizer, Eli Lillly, and AbbVie. The drugs belong to a class of anti-inflammatory drugs known as JAK inhibitors. The FDA cited serious adverse events, including death, in patients 50 and over. The addition of the warning for Xeljanz, follows the FDA's recent review of a February trial which showed an increased risk of cardiac issues associated with the drug. Rinvoq (AbbVie) and Xeljanz (Pfizer) are now only recommended for use in patients who have had inadequate response to a TNF blocker, an alternative class of anti-inflammatory drugs. If you or a loved one has been injured by a dangerous drug or product, contact the experienced attorneys at Keilty Bonadio for a free consultation.